Cargando…

A Citywide Approach to SARS-CoV2 Testing

The COVID-19 pandemic caused more than 30 million infections in the United States between March 2020 and April 2021. In response to systemic disparities in SARS-CoV2 testing and COVID-19 infections, health systems, city leaders and community stakeholders in Worcester, Massachusetts created a citywid...

Descripción completa

Detalles Bibliográficos
Autores principales: Broach, John P., Lowell, Monica, Brown, Olga, Martin, Clayton, Muller, Michelle, Shirshac, Jeanne, Perrone, Domenica, Smith, Will, Castiel, Matilde, Kobayashi, Kimiyoshi J., Lapriore, Cheryl M., Dickson, Eric W., Babu, Kavita M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277977/
https://www.ncbi.nlm.nih.gov/pubmed/34277553
http://dx.doi.org/10.3389/fpubh.2021.695442
_version_ 1783722168410963968
author Broach, John P.
Lowell, Monica
Brown, Olga
Martin, Clayton
Muller, Michelle
Shirshac, Jeanne
Perrone, Domenica
Smith, Will
Castiel, Matilde
Kobayashi, Kimiyoshi J.
Lapriore, Cheryl M.
Dickson, Eric W.
Babu, Kavita M.
author_facet Broach, John P.
Lowell, Monica
Brown, Olga
Martin, Clayton
Muller, Michelle
Shirshac, Jeanne
Perrone, Domenica
Smith, Will
Castiel, Matilde
Kobayashi, Kimiyoshi J.
Lapriore, Cheryl M.
Dickson, Eric W.
Babu, Kavita M.
author_sort Broach, John P.
collection PubMed
description The COVID-19 pandemic caused more than 30 million infections in the United States between March 2020 and April 2021. In response to systemic disparities in SARS-CoV2 testing and COVID-19 infections, health systems, city leaders and community stakeholders in Worcester, Massachusetts created a citywide Equity Task Force with a specific goal of making low-barrier testing available to individuals throughout our community. Within months, the state of Massachusetts announced the Stop the Spread campaign, a state-funded testing venture. With this funding, and through our community-based approach, our team tested more than 48,363 individuals between August 3, 2020 and February 28, 2021. Through multiple PDSA (Plan-Do-Study-Act) cycles, we optimized our process to test close to 300 individuals per hour. Our positivity rate ranged from 1.5% with our initial testing events to a high of 13.4% on January 6, 2021. During the challenges of providing traditional inpatient and ambulatory care during the pandemic, our health system, city leadership, and community advocacy groups united to broaden the scope of care to include widespread, population-based SARS-CoV2 testing. We anticipate that the lessons learned in conducting this testing campaign can be applied to further surges of SARS-CoV2, international environments, and future respiratory disease pandemics.
format Online
Article
Text
id pubmed-8277977
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82779772021-07-15 A Citywide Approach to SARS-CoV2 Testing Broach, John P. Lowell, Monica Brown, Olga Martin, Clayton Muller, Michelle Shirshac, Jeanne Perrone, Domenica Smith, Will Castiel, Matilde Kobayashi, Kimiyoshi J. Lapriore, Cheryl M. Dickson, Eric W. Babu, Kavita M. Front Public Health Public Health The COVID-19 pandemic caused more than 30 million infections in the United States between March 2020 and April 2021. In response to systemic disparities in SARS-CoV2 testing and COVID-19 infections, health systems, city leaders and community stakeholders in Worcester, Massachusetts created a citywide Equity Task Force with a specific goal of making low-barrier testing available to individuals throughout our community. Within months, the state of Massachusetts announced the Stop the Spread campaign, a state-funded testing venture. With this funding, and through our community-based approach, our team tested more than 48,363 individuals between August 3, 2020 and February 28, 2021. Through multiple PDSA (Plan-Do-Study-Act) cycles, we optimized our process to test close to 300 individuals per hour. Our positivity rate ranged from 1.5% with our initial testing events to a high of 13.4% on January 6, 2021. During the challenges of providing traditional inpatient and ambulatory care during the pandemic, our health system, city leadership, and community advocacy groups united to broaden the scope of care to include widespread, population-based SARS-CoV2 testing. We anticipate that the lessons learned in conducting this testing campaign can be applied to further surges of SARS-CoV2, international environments, and future respiratory disease pandemics. Frontiers Media S.A. 2021-06-30 /pmc/articles/PMC8277977/ /pubmed/34277553 http://dx.doi.org/10.3389/fpubh.2021.695442 Text en Copyright © 2021 Broach, Lowell, Brown, Martin, Muller, Shirshac, Perrone, Smith, Castiel, Kobayashi, Lapriore, Dickson and Babu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Public Health
Broach, John P.
Lowell, Monica
Brown, Olga
Martin, Clayton
Muller, Michelle
Shirshac, Jeanne
Perrone, Domenica
Smith, Will
Castiel, Matilde
Kobayashi, Kimiyoshi J.
Lapriore, Cheryl M.
Dickson, Eric W.
Babu, Kavita M.
A Citywide Approach to SARS-CoV2 Testing
title A Citywide Approach to SARS-CoV2 Testing
title_full A Citywide Approach to SARS-CoV2 Testing
title_fullStr A Citywide Approach to SARS-CoV2 Testing
title_full_unstemmed A Citywide Approach to SARS-CoV2 Testing
title_short A Citywide Approach to SARS-CoV2 Testing
title_sort citywide approach to sars-cov2 testing
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277977/
https://www.ncbi.nlm.nih.gov/pubmed/34277553
http://dx.doi.org/10.3389/fpubh.2021.695442
work_keys_str_mv AT broachjohnp acitywideapproachtosarscov2testing
AT lowellmonica acitywideapproachtosarscov2testing
AT brownolga acitywideapproachtosarscov2testing
AT martinclayton acitywideapproachtosarscov2testing
AT mullermichelle acitywideapproachtosarscov2testing
AT shirshacjeanne acitywideapproachtosarscov2testing
AT perronedomenica acitywideapproachtosarscov2testing
AT smithwill acitywideapproachtosarscov2testing
AT castielmatilde acitywideapproachtosarscov2testing
AT kobayashikimiyoshij acitywideapproachtosarscov2testing
AT lapriorecherylm acitywideapproachtosarscov2testing
AT dicksonericw acitywideapproachtosarscov2testing
AT babukavitam acitywideapproachtosarscov2testing
AT broachjohnp citywideapproachtosarscov2testing
AT lowellmonica citywideapproachtosarscov2testing
AT brownolga citywideapproachtosarscov2testing
AT martinclayton citywideapproachtosarscov2testing
AT mullermichelle citywideapproachtosarscov2testing
AT shirshacjeanne citywideapproachtosarscov2testing
AT perronedomenica citywideapproachtosarscov2testing
AT smithwill citywideapproachtosarscov2testing
AT castielmatilde citywideapproachtosarscov2testing
AT kobayashikimiyoshij citywideapproachtosarscov2testing
AT lapriorecherylm citywideapproachtosarscov2testing
AT dicksonericw citywideapproachtosarscov2testing
AT babukavitam citywideapproachtosarscov2testing